This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berger, A. K. Articles by Krumholz, H. M. Search for Related Content PubMed PubMed Citation Articles by Berger, A. K. Articles by Krumholz, H. M.

Thrombolytic therapy in older patients

Alan K. Berger, MD^*, Martha J. Radford, MD, FACC^* , Yun Wang, MS and Harlan M. Krumholz, MD, FACC^*

^* Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
Yale-New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Connecticut, USA
Qualidigm®, Middletown, Connecticut, USA
Section of Chronic Disease Epidemiology, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut, USA

View larger version (20K): [in a new window]   Figure 1 Thirty-day mortality model for patients without absolute contraindications to thrombolytic therapy, stratified by clinical and hospital characteristics. The odds ratio and 95% confidence intervals for thrombolysis (solid line) and primary angioplasty (dashed line) are compared with no reperfusion strategy at 30 days. The results are stratified by clinical and hospital characteristics and also demonstrated for the combined study sample. Points to the left of 1.00 indicate a benefit of the therapy whereas point estimates to the right of 1.00 indicate a detrimental effect.

View larger version (16K): [in a new window]   Figure 2 One-year mortality model for patients without absolute contraindications to thrombolytic therapy, stratified by clinical and hospital characteristics. The odds ratio and 95% confidence intervals for thrombolysis (solid line) and primary angioplasty (dashed line) are compared with no reperfusion strategy at one year. The results are stratified by clinical and hospital characteristics and also demonstrated for the combined study sample. Points to the left of 1.00 indicate a benefit of the therapy whereas point estimates to the right of 1.00 indicate a detrimental effect.